P. Gómez Pardo - Concepedia

Concepedia

Author

P. Gómez Pardo

Vall d'Hebron Hospital Universitari ORCID

Also Known As

Angeles Peñuelas, Elena Garralda, M. Roca Herrera, Miriam Arumí, P Gomez Pardo, P. G. Pardo, P. Gomez Pardo, P. Gómez Pardo, P. Pardo, Patricia Gomez Pardo

56

Publications

1.2K

Citations

10

H-Index

21

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Heidelberg University Massachusetts General Hospital Hospital Universitario 12 De Octubre Centre Léon Bérard

PG

About

P. Gómez Pardo is an author at Vall d'Hebron Hospital Universitari specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	344
2	Health Sciences	3	3	167
3	Immunology	2	2	131
4	Hepatology	1	1	23
5	Obstetrics	1	1	110

P. Gómez Pardo

×

11

Publications

1.2K

Citations

10

H-Index

	Year	Citations
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hope S. Rugo, Aditya Bardia, Frederik Marmé, The Lancet	2023	363
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hope S. Rugo, Aditya Bardia, Frederik Marmé, Journal of Clinical Oncology	2022	275
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial Sònia Pernas, Miguel Martín, Peter A. Kaufman, The Lancet Oncology Breast OncologyOncologyMedicineBreast CancerPharmacotherapy	2018	133
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study Giuseppe Curigliano, P. Gómez Pardo, Funda Meric‐Bernstam, The Breast	2016	132
Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Hope S. Rugo, Aditya Bardia, Frederik Marmé, Journal of Clinical Oncology Breast OncologyPrimary ResultsCancer ManagementImmunologyGynecology	2022	110
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). Sara M. Tolaney, Aditya Bardia, Frederik Marmé, Journal of Clinical Oncology Breast OncologyCancer ManagementPathologyPharmacotherapyTropics-02 Study	2023	32
Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease Angélica Romero Daza, Aalap Chokshi, P. Gómez Pardo, Journal of Cardiovascular Magnetic Resonance	2021	27
Defining the optimal sequence for the systemic treatment of metastatic breast cancer Joan Albanell Mestres, A. B. iMolins, Eva Ciruelos Gil, Clinical & Translational Oncology Optimal SequenceMetastatic Breast CancerBreast OncologyMedicineSystemic Treatment	2016	25
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib Nagdeep Giri, Joanna C. Masters, Anna Plotka, Investigational New Drugs HepatologyPharmacological StudyLiver PhysiologyPharmacologyHepatic Impairment	2015	23
Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) Hope Rugo, Aditya Bardia, Frederik Marmé, Cancer Research Breast OncologyAbstract Gs1-11Sacituzumab GovitecanMedicineCancer Management	2023	21

Page 1